The ability of nanoparticles containing a pH sensitive ART derivative to down-regulate HER1, HER2, and HER3, as well as other proteins linked to neoplasia, suggests that this approach has real therapeutic potential for treatment of specific breast cancer subtypes. This evidence concerns the gene ERBB2 and breast carcinoma.